


Volume **6**

Molecular Medicine and  
Medicinal Chemistry

# Fluorine in Pharmaceutical and Medicinal Chemistry

From Biophysical Aspects  
to Clinical Applications



Véronique Gouverneur  
Klaus Müller

Editors

Imperial College Press

Volume **6**

**Molecular Medicine and  
Medicinal Chemistry**

# Fluorine in Pharmaceutical and Medicinal Chemistry

From Biophysical Aspects  
to Clinical Applications



**Véronique Gouverneur**

*University of Oxford, UK*

**Klaus Müller**

*F Hoffmann-La Roche AG, Switzerland*

Editors

ICP

Imperial College Press

# Foreword

*François Diederich*

For almost a century after the first preparation of elemental  $F_2$  by Moissan in 1886, synthetic fluorine chemistry was pursued and developed by a small community of experts capable of handling the aggressive gas using special laboratory equipment. Important technological developments resulted from this work, such as the bulk-scale preparation of fluorinated hydrocarbons for refrigerators and other cooling devices, which, however, later became banned due to their atmospheric greenhouse effects and the depletion of the ozone layer. Nonetheless, lasting successful applications resulted, for example, from the development of fluorinated polymers such as Teflon®, of volatile gases for anesthesia, and of the separation of uranium isotopes using  $UF_6$  centrifuges, for the production of nuclear fuel for use in powerplants.

The development of fluorine-containing drugs started in 1957 and was in the following years strongly aided by the increasing availability of commercial fluorinating agents allowing the safe and selective introduction of organofluorine, i.e. C–F bonds, using common laboratory equipment. This has resulted in the introduction of over 150 fluorinated drugs to the market, and currently nearly 20% of all pharmaceuticals and 40% of all agrochemicals in development contain organofluorine.

The reasons for this explosive growth in interest in the introduction of organofluorine are multiple. While beneficial effects on ADME (absorption, distribution, metabolism, and excretion) and safety were recognized earlier on, the interest in organofluorine has lately focused on more atom-based properties, such as distinct conformational and stereo-electronic properties, modulation of the  $pK_a$ -value of neighboring

# Contents

Foreword	v
<i>François Diederich</i>	
Preface	xi
<i>Véronique Gouverneur and Klaus Müller</i>	
<b>Section 1</b>	<b>1</b>
1 Synthesis and Properties of Fluorinated Nucleobases in DNA and RNA	3
<i>Holger Gohlke, Jelena Bozilovic and Joachim W. Engels</i>	
1.1 Introduction	3
1.2 Fluorine in Molecular Recognition	4
1.3 Synthesis of Fluoro-Substituted Benzenes, Benzimidazoles and Indoles, and their Incorporation into Model RNA	6
1.3.1 Chemical syntheses of fluoro-substituted benzenes, benzimidazoles and indoles	6
1.3.2 Synthesis of 12-mer RNA duplexes that incorporate fluoronucleosides	12
1.3.3 RNA melting studies and thermodynamic data	13
1.4 Origin of the Molecular Recognition Properties of Fluorinated Nucleobases	16
1.4.1 Stacking and desolvation: Insights from thermodynamic analyses	16
1.4.2 C–H···F–C interactions: Crystallographic analysis of fluoro-substituted NNIs	17

1.4.3	Molecular dynamics simulations and free energy calculations	20
1.5	Incorporation of Fluoro-Substituted NNI into the Hammerhead Ribozyme and siRNA Constructs and their Acceptance by Polymerases	22
1.5.1	Hammerhead ribozyme	22
1.5.2	Fluorobenzene and benzimidazoles in RNA interference and siRNA	24
1.5.3	Polymerase acceptance of fluorobenzimidazoles	26
1.6	Conclusion	26
	Acknowledgements	27
	References	27
2	Molecular Interactions of Fluorinated Amino Acids within the Hydrophobic Core of a Coiled Coil Peptide	33
	<i>Toni Vagt, Mario Salwiczek and Beate Kokschn</i>	
2.1	Introduction	33
2.2	The $\alpha$ -Helical Coiled Coil as a Model System to Investigate Fluorinated Amino Acids within a Native Protein Environment	35
2.3	Single Fluoroamino Acid Substitutions within a Heterodimeric Coiled Coil	39
2.3.1	The $\alpha$ -helical coiled coil as a model for a natural protein environment	39
2.4	Biophysical Characterisation of the Interactions	41
2.4.1	Hydrophobicity of the fluorinated amino acids	41
2.4.2	The impact of fluorine substitutions on coiled coil structure	44
2.4.3	The impact of fluorine substitutions on the thermodynamic stability of the dimer	47
2.5	Screening for Native Interaction Partners	52
2.6	Conclusions and Outlook	57
	Acknowledgements	58
	References	58

3	Probing the Binding Affinity and Proteolytic Stability of Trifluoromethyl Peptide Mimics as Protease Inhibitors <i>Matteo Zanda, Alessandro Volonterio, Monica Sani and Sergio Dall'Angelo</i>	63
3.1	Introduction	63
3.2	Peptidyl Trifluoro-Ketones	64
3.3	Peptidomimetics Containing the Trifluoroethylamine Function as Peptide Bond Replacement	66
3.4	Trifluoromethyl-Peptidomimetics as Protease Inhibitors	73
3.4.1	MMP inhibitors	73
3.4.2	$\beta$ -Fluoroalkyl $\beta$ -sulfonyl hydroxamates	75
3.4.3	Dual ACE/NEP inhibitors	77
3.4.4	Crystallographic analysis of the role of the CF <sub>3</sub> -group in the binding process to enzyme active sites	80
	References	86
4	Trifluoromethyl-Substituted $\alpha$ -Amino Acids as Solid-State <sup>19</sup> F NMR Labels for Structural Studies of Membrane-Bound Peptides <i>Vladimir S. Kubyshkin, Igor V. Komarov, Sergii Afonin, Pavel K. Mykhailiuk, Stephan L. Grage and Anne S. Ulrich</i>	91
4.1	Introduction	91
4.2	Solid-State NMR for Structure Analysis of Membrane-Associated Polypeptides	93
4.3	Choice of the CF <sub>3</sub> Group as a Label for <sup>19</sup> F NMR of Peptides in Membranes	96
4.4	Suitable CF <sub>3</sub> -Labelled Amino Acids for <sup>19</sup> F NMR Analysis	98
4.5	$\alpha$ -CF <sub>3</sub> -Substituted Amino Acids: TfmAla	99
4.5.1	Synthesis	99
4.5.2	Separation of the TfmAla enantiomers	106
4.5.3	Incorporation of TfmAla into peptides	107
4.5.4	<sup>19</sup> F NMR structure analysis of peptides with TfmAla	109

4.6	Amino Acids with a Rigid Spacer Between C $\alpha$ and the CF <sub>3</sub> Group: 4-TfmPhg and TfmBpg	111
4.6.1	Synthesis of 4-TfmPhg	111
4.6.2	Separation of the 4-TfmPhg enantiomers	117
4.6.3	Incorporation of 4-TfmPhg into peptides	118
4.6.4	Synthesis of TfmBpg	120
4.6.5	Synthesis of peptides containing TfmBpg	121
4.6.6	<sup>19</sup> F NMR structure analysis of peptides with 4-TfmPhg and TfmBpg	122
4.7	Conclusions and Perspectives	124
	Acknowledgements	128
	References	128
<b>Section 2</b>		<b>139</b>
5	Fluorine-Containing Pharmaceuticals <i>Steve Swallow</i>	141
5.1	Introduction	141
5.1.1	Survey of fluorine-containing pharmaceuticals	142
5.2	Case Studies	144
5.2.1	Ezetimibe (Zetia)	144
5.2.2	Celecoxib (Celebrex)	147
5.2.3	Sitagliptin (Januvia)	147
5.2.4	Fluconazole (Diflucan) and Voriconazole (Vfend)	154
5.2.5	Fluoroquinolones	158
5.2.6	Fluticasone propionate (Flovent, Flixotide)	160
5.2.7	Aprepitant (Emend)	165
5.3	Summary and Future Outlook	169
	References	170
6	Applications of Pentafluorosulfanyl Substitution in Life Sciences Research <i>John T. Welch</i>	175
6.1	Introduction	175
6.2	General Preparative Information	177

6.2.1	Synthesis of 1-fluoro-4-nitro-2-(pentafluorosulfanyl)benzene and derivatives	178
6.2.2	<i>Synthesis of 4,5-dihydroisoxazoles with allylic pentafluorosulfanyl substituents</i>	178
6.2.3	Pentafluorosulfanyl (SF <sub>5</sub> ) pyrrole carboxylic acid esters	179
6.3	Agrochemical Applications	180
6.3.1	3-(2-Chloro-4-(pentafluorosulfanyl)phenoxy) benzoic acid	180
6.3.2	Pentafluorosulfanylphenyl and benzoylisoxazoles	181
6.3.3	Trifluralin analogue	182
6.3.4	Insecticidal derivatives of substituted phosphorylated phenylalkyl iminooxazolines and iminothiazolines	183
6.3.5	Fungicidal (E)-methyl 2-(2-(3-(pentafluorosulfanyl)phenoxy)methyl) phenyl)-3-methoxyacrylate, 44	183
6.3.6	N-(3-Phenylpropyl) and (3-phenylethyl) benzamides	184
6.4	Medicinal Chemistry	184
6.4.1	1-(Pentafluorosulfanylphenyl)-3-(1,2,4-triazol-3-ylthioalkyl)-3-azabicyclo[3.1.0]hexanes, dopamine D <sub>3</sub> receptor modulators	185
6.4.2	Pentafluorosulfur piperazinyloperidines	186
6.4.3	Pentafluorosulfanyl arene containing pyrazoles	187
6.4.4	N-(phenoxycyanomethylethyl) (pentafluorosulfanyl) benzamide	187
6.4.5	Preparation of pentafluorosulfanyl-substituted compounds for use as vanilloid receptor VR1 ligands	188
6.4.6	4-Fluoro-N-(4-pentafluorosulfanylphenyl)-4-(3-fluoropyridin-2-yl) cyclohexanecarboxamide 84	189
6.4.7	Pentafluorosulfanylarene aminoimidazoles	190
6.4.8	3-Phenylhydantoins	191



6.4.9	Pentafluorosulfanyl benzoylguanidines	192
6.4.10	Pentafluorosulfanylphenoxy-substituted benzoylguanidines	193
6.4.11	Functionalization of pentafluorosulfanylphenoxy-substituted benzoylguanidines	193
6.4.12	Pentafluorosulfanyl-containing diarylamine trypanothione reductase inhibitors	193
6.4.13	A pentafluorosulfanyl-containing quinoline, a mefloquine analogue	196
6.4.14	Fluoxetine analogues	197
6.4.15	Fenfluramine and norfenfluramine	199
6.4.16	5-Hydroxytryptamine	200
6.5	Conclusions and Outlook	202
	Acknowledgements	202
	References	202
7	Strategic Incorporation of Fluorine into Taxoid Anticancer Agents	209
	<i>Antonella Pepe, Liang Sun and Iwao Ojima</i>	
7.1	Introduction	209
7.2	Paclitaxel, Docetaxel and New-Generation Taxoids	210
7.3	Synthesis and Biological Evaluation of Fluorine-Containing New-Generation Taxoids	213
7.4	Synthesis and Biological Evaluation of Fluorine-Containing C-Seco-Taxoids	221
7.5	Use of Solid-State $^{19}\text{F}$ NMR and Computational Analysis for the Determination of Bioactive Conformation of Paclitaxel and Fluorinated Taxoids	226
7.6	Use of Fluorine in Tumour-Targeting Anticancer Agents	232
	Acknowledgements	234
	References	235

8	Synthesis and Antiviral, Antitumour Activities of Fluorinated Sugar Nucleosides	241
	<i>Feng Zheng, Xiao-Long Qiu and Feng-Ling Qing</i>	
8.1	Introduction	241
8.2	Nucleosides Fluorinated at C2'	242
8.2.1	2'- $\alpha$ -Fluoro nucleosides	243
8.2.2	2'- $\beta$ -Fluoro nucleosides	246
8.2.3	2', 2'-Difluoronucleosides	250
8.2.4	2'-Fluoro-2',3'-didehydro-2',3'-dideoxy nucleosides	252
8.3	Nucleosides Fluorinated at C3'	254
8.3.1	3'- $\alpha$ -Fluoro nucleosides	254
8.3.2	3'- $\beta$ -Fluoro nucleosides	256
8.3.3	3',3'-Difluoro nucleosides	258
8.3.4	3'-Fluoro-2', 3'-didehydro-2', 3'-dideoxy nucleosides	260
8.4	Nucleosides Fluorinated at C4'	261
8.5	Nucleosides Fluorinated at C6'	263
8.6	5'-Fluorinated and Phosphonodifluoromethylenated Nucleosides	269
8.7	Nucleosides Bearing Exocyclic Fluorocarbon Substituents at C2', C3' and C4'	272
8.7.1	Nucleosides containing a trifluoromethyl group	272
8.7.2	Nucleosides containing a difluoromethylene, fluoromethylene or difluoromethyl group	274
8.8	Other Fluorinated Nucleosides	276
8.8.1	Fluorinated cyclopropyl nucleosides	276
8.8.2	Fluorinated cyclobutyl and oxetanosyl nucleosides	278
8.8.3	Fluorinated pyranosyl nucleosides	278
8.9	Conformational Studies of Fluorinated Nucleosides	280
8.10	Conclusion	284
	References	284

9	Synthesis of Fluorinated Neurotransmitter Analogues	299
	<i>Margit Winkler and David O'Hagan</i>	
9.1	Introduction	299
9.2	Adenosine Receptors	300
9.3	Adrenoreceptors	305
9.3.1	Epinephrine (adrenaline)	305
9.3.2	Norepinephrine (noradrenaline)	306
9.3.3	Octopamine	307
9.3.4	Tyramine	308
9.4	Cannabinoid Receptors	308
9.5	Dopamine Receptors	310
9.5.1	Dopamine	310
9.5.2	L-DOPA	311
9.6	GABA Receptors	312
9.7	Glutamate Receptors	314
9.8	Histamine Receptors	317
9.9	Muscarinic Receptors	318
9.10	Nicotinic Acetylcholine Receptors	319
9.11	Serotonin Receptors	321
9.12	Melatonin Receptors	323
9.13	Vanilloid Receptors	323
9.14	Capsaicin	323
9.15	Anandamide	324
9.16	Conclusion	324
	References	325
	<b>Section 3</b>	<b>333</b>
10	$^{18}\text{F}$ -Radionuclide Chemistry	335
	<i>Romain Bejot and Véronique Gouverneur</i>	
10.1	Introduction	335
10.1.1	Radioisotope $^{18}\text{F}$	335
10.1.2	Nuclear reactions	335
10.1.3	Production of $^{18}\text{F}$	337
10.1.4	Positron emission tomography (PET)	338

	10.1.5	Specific activity	339
	10.1.6	Kinetics and radiochemical yield	341
10.2		Carrier-Added $^{18}\text{F}$ -Labelled Probes	342
	10.2.1	Carrier-added [ $^{18}\text{F}$ ]fluoride	342
	10.2.2	Surface interactions with $^{18}\text{F}$ -labelled probes	344
	10.2.3	Catalytic fluorination	345
10.3		Nucleophilic $^{18}\text{F}$ -Radiolabelling	345
	10.3.1	Reactive [ $^{18}\text{F}$ ]fluoride	346
	10.3.2	Nucleophilic carbon–fluorine bond formation	348
	10.3.3	Silicon–fluorine bond formation	357
	10.3.4	Boron–fluorine bond formation	358
	10.3.5	Aluminium–fluorine bond formation	359
	10.3.6	Phosphorus–fluorine bond formation	359
10.4		Electrophilic $^{18}\text{F}$ -Radiolabelling	360
	10.4.1	Electrophilic fluorination agents	360
	10.4.2	Electrophilic carbon–fluorine bond formation	364
10.5		Prosthetic Groups	367
10.6		Purification	369
		Acknowledgements	370
		References	370
11		$^{18}\text{F}$ -Labelled Tracers for PET Oncology and Neurology Applications	383
		<i>Sajinder K. Luthra and Edward G. Robins</i>	
	11.1	Introduction to Molecular Imaging	383
	11.2	Positron Emission Tomography (PET)	384
	11.3	Biological Imaging Targets	385
	11.4	Tracer Development	385
	11.5	Oncology Applications	388
	11.6	2- $^{18}\text{F}$ Fluoro-2-Deoxy-D-Glucose ( $^{18}\text{F}$ FDG)	389
	11.7	3'-Deoxy-3'- $^{18}\text{F}$ Fluoro-L-Thymidine ( $^{18}\text{F}$ FLT)	391
	11.8	Imaging Tumour Angiogenesis	396
	11.9	Choline Metabolism	404
	11.10	Apoptosis	408
		11.10.1 PS targeting radiotracers	408

11.11	Caspase Targeting Radiotracers	411
11.12	CNS Neurosciences Applications	413
11.13	Beta-Amyloid Plaques and Neurofibrillary Tangles	414
11.13.1	FDDNP	415
11.13.2	BTA derivatives	417
11.13.3	Stilbenes	421
11.14	Peripheral Benzodiazepine Binding Sites or TSPO-18kDa	423
11.14.1	Aryloxyanilide-based ligands	424
11.14.2	[ <sup>18</sup> F]FEDAA1106	425
11.14.3	[ <sup>18</sup> F]FEAC and [ <sup>18</sup> F]FEDAC	426
11.14.4	PBR06	426
11.14.5	[ <sup>18</sup> F]FEPPA	428
11.14.6	Pyrazolopyrimidine ligands	429
11.15	Serotonin 5-HT <sub>1A</sub> Antagonists and Agonists	431
11.16	Imaging the Cannabinoid 1 Receptor (CB <sub>1</sub> )	435
11.17	Ion Channels	440
11.18	Summary	440
	Acknowledgements	441
	References	441
12	<sup>19</sup> F NMR: Clinical and Molecular Imaging Applications <i>Vikram D. Kodibagkar, Rami R. Hallac, Dawen Zhao, Jian-Xin Yu and Ralph P. Mason</i>	461
12.1	Introduction	461
12.2	Clinical Applications and Drug Metabolism	468
12.3	Reporter Molecule Strategies	473
12.3.1	Physical interactions	474
12.3.2	Chemical association	480
12.3.3	Chemical interactions	484
12.4	Passive Reporter Molecules	490
12.5	Recent Innovations, Novelty and Future Improvements	492
12.5.1	Chemistry and molecular engineering	492
12.5.2	Biology	495

12.5.3	Physics	496
12.5.4	Innovative new applications	496
12.6	Context of $^{19}\text{F}$ NMR in Biomedicine Today	497
	Acknowledgments	500
	References	500
	Index	525